Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abiomed AbioCor

This article was originally published in The Gray Sheet

Executive Summary

A humanitarian device exemption will be submitted to FDA by the end of 2003, contingent on patient experiences in the ongoing clinical trial and on FDA approval of a qualifying population, Danvers, Mass.-based firm tells Banc of America Securities conference attendees in Las Vegas March 25. The firm expects to implant eight more AbioCor hearts in the U.S. and Europe this year for a total of 15 (1"The Gray Sheet" March 17, 2003, p. 17)...
Advertisement

Related Content

Abiomed AB5000 Circulatory Support System Will Aid BVS Blood Pump Line
Abiomed AB5000 Circulatory Support System Will Aid BVS Blood Pump Line
Advertisement
UsernamePublicRestriction

Register

MT018100

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel